The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AlphaBet: A phase I/II trial evaluating the combination of radium-223 and [177Lu]Lu-PSMA-I&T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Louise Kathleen Kostos
Honoraria - Bayer
 
James Patrick Buteau
No Relationships to Disclose
 
Theresa Yeung
No Relationships to Disclose
 
Sophia Xie
No Relationships to Disclose
 
Juliana Di Iulio
No Relationships to Disclose
 
Anthony Cardin
No Relationships to Disclose
 
Katie Owen
No Relationships to Disclose
 
Heidi Fettke
No Relationships to Disclose
 
Kwang Y Chin
No Relationships to Disclose
 
Brittany Emmerson
No Relationships to Disclose
 
Mohammad B Haskali
Patents, Royalties, Other Intellectual Property - I hold multiple patents
 
Belinda Parker
Consulting or Advisory Role - Tallac Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Peter Mac Callum Cancer Centre, Prelude Dx
 
Luc Furic
Employment - CSL Behring (I)
Stock and Other Ownership Interests - CSL Behring (I)
Research Funding - Pimera Pty Ltd, Senhwa Biosciences, Isotopia Molecular Imaging
Patents, Royalties, Other Intellectual Property - Abbvie (I)
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Michael S Hofman
Consulting or Advisory Role - Endocyte; Janssen; POINT Biopharma
Speakers' Bureau - Astellas Pharma; AstraZeneca; Janssen; Mundipharma
Research Funding - Advanced Accelerator Applications/Novartis (Inst); Bayer (Inst); Endocyte (Inst)
Travel, Accommodations, Expenses - Genzyme; Ipsen; Janssen